Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-00101 Vaccine in HPV 16 Positive Women With ASCUS/LSIL
NCT00091130Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Jun 2007
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of verpasep caltespen in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), sponsored by National Cancer Institute. Started Sep 2004; status: completed.
02
Drugs
verpasep caltespen
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT00091130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091130.